Filing Flows › Comparisons › ACCS vs PBSV
Access Newswire vs Pharma-Bio Serv: ACCS and PBSV compared
Access Newswire is the larger company: $5.6M of revenue in its latest quarter (Q2 2026) against $2.3M for Pharma-Bio Serv (Q3 FY26). Pharma-Bio Serv is growing faster (+19% against -0.1% a year earlier). Pharma-Bio Serv is more profitable, with an operating margin of -3.1% against -5.5%.
Where the money goes: ACCS and PBSV
Access Newswire (ACCS) · Q2 2026
Access Newswire, Q2 2026: revenue $5.6M (-0.1% year over year), operating margin -5.5%, net loss $482K, operating cash flow $173K. The chart follows the revenue to costs, profit and cash.
Pharma-Bio Serv (PBSV) · Q3 FY26
Pharma-Bio Serv, Q3 FY26: revenue $2.3M (+19% year over year), operating margin -3.1%, net loss $14K, operating cash flow $61K. The chart follows the revenue to costs, profit and cash.
| Access Newswire (ACCS) | Pharma-Bio Serv (PBSV) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 FY26 |
| Revenue | $5.6M | $2.3M |
| Revenue growth, Y/Y | -0.1% | +19% |
| Operating margin | -5.5% | -3.1% |
| Net earnings | −$482K | −$14K |
| Net margin | -8.6% | -0.6% |
| Operating cash flow | $173K | $61K |
| Free cash flow | $160K | $60K |
Questions
Which is bigger, Access Newswire or Pharma-Bio Serv?
Access Newswire is the larger company: $5.6M of revenue in its latest quarter (Q2 2026) against $2.3M for Pharma-Bio Serv (Q3 FY26).
Is Access Newswire or Pharma-Bio Serv growing faster?
Pharma-Bio Serv is growing faster (+19% against -0.1% a year earlier).
Which is more profitable, Access Newswire or Pharma-Bio Serv?
Pharma-Bio Serv is more profitable, with an operating margin of -3.1% against -5.5%.
More: Access Newswire earnings · how Access Newswire makes money · Pharma-Bio Serv earnings · how Pharma-Bio Serv makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 11, 2026; 10-Q filed Sep 14, 2026). Fiscal quarters can end on different dates. Not investment advice.